Literature DB >> 2221845

Soluble interleukin-2 receptors in cerebrospinal fluid from individuals with various neurological disorders.

S D Kittur1, D S Kittur, T T Soncrant, S I Rapoport, W W Tourtellotte, J E Nagel, W H Adler.   

Abstract

Soluble interleukin-2 (IL-2R) levels in the cerebrospinal fluid (CSF) were studied in infectious, inflammatory, degenerative, and neoplastic disorders to evaluate their usefulness as a marker for the presence of activated T cells, thus indicating an inflammatory process. CSF from control subjects and patients with stationary, progressive, and treated multiple sclerosis (MS); aseptic meningitis; lymphoid and nonlymphoid central nervous system (CNS) tumors; Alzheimer's disease, as well as serum from MS patients and control subjects were studied for levels of soluble IL-2R. A significant increase in CSF IL-2R levels was observed in patients with MS, meningitis, and lymphoid CNS tumors; the MS group showed the highest values. CSF from individuals with Alzheimer's disease and from patients with nonlymphoid tumors did not show significantly elevated values. Serum IL-2R levels were significantly higher in MS patients than in control subjects, but there was no significant correlation between individual serum and CSF IL-2R levels. This study suggests the presence of activated T-lymphocytes in the CNS of patients with MS.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2221845     DOI: 10.1002/ana.410280209

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  11 in total

1.  Low serum interleukin-10 levels in multiple sclerosis: further evidence for decreased systemic immunosuppression?

Authors:  A Salmaggi; A Dufour; M Eoli; E Corsini; L La Mantia; G Massa; A Nespolo; C Milanese
Journal:  J Neurol       Date:  1996-01       Impact factor: 4.849

2.  Optic neuritis in different strains of mice by a recombinant HSV-1 expressing murine interleukin-2.

Authors:  Mandana Zandian; Raelene Belisle; Kevin R Mott; Steven Nusinowitz; Florence M Hofman; Homayon Ghiasi
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-02-21       Impact factor: 4.799

3.  Measurement of immune markers in the serum and cerebrospinal fluid of multiple sclerosis patients during clinical remission.

Authors:  C E Shaw; P R Dunbar; H A Macaulay; T J Neale
Journal:  J Neurol       Date:  1995-01       Impact factor: 4.849

4.  Impact of a Demyelination-Inducing Central Nervous System Virus on Expression of Demyelination Genes in Type 2 Lymphoid Cells.

Authors:  Satoshi Hirose; Mihoko Kato; Kati Tormanen; Pedram Shafiei Jahani; Omid Akbari; Homayon Ghiasi
Journal:  J Virol       Date:  2021-01-28       Impact factor: 5.103

Review 5.  Cerebrospinal fluid (CSF) analyses in HIV-1 primary neurological disease.

Authors:  J Nogales-Gaete; K Syndulko; W W Tourtellotte
Journal:  Ital J Neurol Sci       Date:  1992-11

6.  Correlation of interleukin-2 and soluble interleukin-2 receptor with clinical activity of multiple sclerosis.

Authors:  M K Sharief; E J Thompson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-02       Impact factor: 10.154

7.  Role of interleukin-2 and herpes simplex virus 1 in central nervous system demyelination in mice.

Authors:  Kevin R Mott; Mandana Zandian; Sariah J Allen; Homayon Ghiasi
Journal:  J Virol       Date:  2013-08-28       Impact factor: 5.103

8.  In vivo relationship of interleukin-2 and soluble IL-2 receptor to blood-brain barrier impairment in patients with active multiple sclerosis.

Authors:  M K Sharief; R Hentges; M Ciardi; E J Thompson
Journal:  J Neurol       Date:  1993-01       Impact factor: 4.849

Review 9.  Autoimmune disease and the nervous system. Biochemical, molecular, and clinical update.

Authors:  J E Merrill; M C Graves; D G Mulder
Journal:  West J Med       Date:  1992-06

10.  Suppression of IL-12p70 formation by IL-2 or following macrophage depletion causes T-cell autoreactivity leading to CNS demyelination in HSV-1-infected mice.

Authors:  Dhong Hyun Lee; Mandana Zandian; Jane Kuo; Kevin R Mott; Shuang Chen; Moshe Arditi; Homayon Ghiasi
Journal:  PLoS Pathog       Date:  2017-05-22       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.